ClinicalTrials.gg
CompletedNCT05598736Updated Oct 19, 2026

Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain

An interventional study of FlowOx 2.0 in Multiple Sclerosis, Spasticity, Muscle and Pain, sponsored by Otivio AS. Completed at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Otivio AS · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.

Enrollment
36th of 43
58 · median 300
Started
2022
with 2 others
No phase
9 of 56
none open now
Registered
51st of 56
by date

Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 36th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 with no phase, and was the 51st registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Multiple Sclerosis with a site in Norway, or all of them as a file.
02

Study summary

This study is based on a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS) (NCT05562453). The investigational device (FlowOx2.0™) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the same pressure chamber but be randomized to either a Control Unit that generates intermittent negative pressure (INP) of - (minus) 40 mmHg or a Control Unit that generates INP of - 10 mmHg. FlowOx2.0™ generating -40 mmHg is the investigational device, and FlowOx2.0™ generating -10 mmHg, is the comparator device. After the initial 4-week double-blind period (NCT05562453), all participants will be offered the -40mmHg control unit to be used during a 6-months optional extension part. The participants who volunteer to continue in the 6-months optional extension part will be included in this study.

Read the detailed description

FlowOx2.0™ is a commercially available device for home treatment of peripheral arterial disease. It is designed to be used at home by patients and has been shown to cause rapid changes in blood flow velocity in the treated leg. Recently, individuals with multiple sclerosis have reported a positive impact on their self-perceived spasticity and pain levels. The study will recruit patients from Norway, Sweden, and Denmark. All subjects will be instructed to treat the most affected leg for 60 minutes per day, preferentially in the evening. The same leg should be treated throughout the study period. A 4-week double-blind part (NCT05562453) is followed by this open investigation in which all randomized subjects that have completed the main part are offered to continue for an additional 6 months using the active device (INP of - 40 mmHg).

03

Conditions studied

  • Multiple Sclerosis
  • Spasticity, Muscle
  • Pain
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subjects must meet all the following criteria to be eligible to participate in the clinical investigation:

  1. Diagnosed MS according to revised McDonald criteria.
  2. Give written .
  3. Age 18-70 years.
  4. Stable MS disease without attack within the last three months.
  5. Ability to perform the walk tests:

    1. 2-minute walk test, and
    2. 25-Foot walk.
  6. Self-reported spasticity in the most affected leg that would be subject to treatment at baseline with a score of ≥ 4, scored using the numeric rating scale (NRS) during the last 24 hours.
  7. Pain and/or discomfort related to the spasticity described in inclusion criteria 6., over the last 7 days using the numeric rating scale (NRS).
  8. Stable and unchanged treatment of spasticity and pain the last month, as judged by the Investigator.
  9. Stable and unchanged disease-modulating treatment for MS last 6 months, as judged by the Investigator.
  10. Can self-manage study equipment.
  11. Willingness and ability to comply with study procedures, visit schedules, and requirements.
  12. Conducted the 4-week double-blind part of the study (NCT05562453).

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria will not be permitted to participate in the clinical investigation:

  1. Have spasticity due to a disease other than MS.
  2. Pregnancy or planned pregnancy within the upcoming study period, up to 7 months (includes the optional extension part).
  3. Have an ongoing infection that subjectively affects their MS state, as judged by the Investigator.
  4. Have received botulinum toxin injection for spasticity within the last 4 months.
  5. Have symptoms or illness that make it difficult to participate in the study, as judged by the Investigator.
  6. Having planned surgery or other treatment within the coming study period of up to 7 months that makes it difficult to participate in the study, as judged by the Investigator.
  7. Subjects with uncontrolled wound infections or infections in the skin of the treated leg.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Investigational device

    FlowOx 2.0 (-40mmHg intermittent negative pressure)

    Device: FlowOx 2.0

Interventions

  • DeviceFlowOx 2.0

    -40mmHg intermittent negative pressure for 60 minutes per day

06

What researchers measure

Primary outcomes

  1. Change in self-reported spasticity using Numeric Rating Scale (NRS)

    Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome the last 24 hours. The scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst imaginable spasticity. The scoring should be done at roughly the same time of day and not during or immediately after treatment.

    Time frame: 6 months

Secondary outcomes

  1. Change in self-reported pain using NRS for subjects with a baseline NRS ≥4.

    Pain is scored using the NRS which describes the average score of pain over the last 24 hours. The scale scores pain from 0-10, where 0 is no pain, and 10 is worst imaginable pain. The scoring is done each day of the study. The scoring should be done roughly at the same time and not during or immediately after treatment.

    Time frame: 6 months

  2. Frequency of adverse events

    All incidences of adverse events (AEs) and device deficiencies (DDs) will be documented and reported during the clinical investigation. At visits and phone calls, study staff will ask whether the subject has experienced any AEs/DDs since the last call/visit. Staff will also follow-up any previous AEs during visits and calls, i.e., are AEs resolved or still ongoing. The subjects will also be encouraged to call and report between visits and calls.

    Time frame: 6 months

  3. Change in timed 25-foot walk (T25-FW)

    The Timed 25-Foot Walk (T25-FW). The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-Foot Walk. The subject is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the subject has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The "score" is the average of these two walks. Subjects may use assistive devices when doing this task. Staff record the average T25-FW score in seconds.

    Time frame: 6 months

  4. Change in 2-minute walking tests

    The 2-min walk test, should be tested in a hallway free of obstacles. Subject instruction will be: "Cover as much ground as possible over 2 minutes. Walk continuously, if possible, but do not be concerned if you need to slow down or stop to rest. The goal is to feel at the end of the test that more ground could not have been covered in the 2 minutes.

    Time frame: 6 months

  5. Change in health-related quality of life measured by Multiple sclerosis impact scale (MSIS-29)

    The MSIS-29 is a measure of the physical and psychological impact of multiple sclerosis (MS) from the patients' perspective. Twenty-nine (29) questions are responded by the subject by circling the number that best describes the subject's situation (graded 1-5, where 1 is "not at all" and 5 is extremely). It captures the subject's views about the impact of MS on his/her day-to-day life during the past two weeks.

    Time frame: 6 minths

  6. Change in health-related quality of life measured by EQ-5D-5L

    The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).

    Time frame: 6 months

  7. Change in Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item measure designed to assess anxiety and depression symptoms in medical patients, with emphasis on reducing the impact of physical illness on the total score. Items are rated on a 4-point severity scale. The HADS produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states.

    Time frame: 6 months

Other outcomes

  1. The proportion of subjects with ≥ 30% improvement in self-reported pain using NRS

    The endpoint will be assessed as described under the primary endpoint

    Time frame: 6 months

  2. Mean daily treatment time

    The control unit records daily use, frequency of use per day and errors (periods without predefined pressure generated). The data will be compiled and used to ensure compliance.

    Time frame: 6 months

  3. Proportion of subjects who wish to continue treatment with FlowOx2.0 beyond 4 weeks

    The number of individuals interested in continuing treatment is expected to reflect a potential benefit. The information will be tabled.

    Time frame: 6 months

  4. Change in medication use for spasticity and pain

    During the enrolment visit, medication use for spasticity and pain will be registered. The same will be recorded at subsequent visits.

    Time frame: 6 months

  5. Change of self-reported sleep quality using the NRS

    Sleep quality is scored using the NRS which describes the average score of sleep over the last 24 hours. The scale scores sleep quality from 0-10, where 0 is the best possible sleep, and 10 is the worst imaginable sleep. The scoring should be done roughly at the same time during the day.

    Time frame: 6 months

  6. Change in fatigue using the NRS

    Fatigue is scored using the NRS which describes the average score of fatigue over the last 24 hours. The scale scores fatigue from 0-10, where 0 is no fatigue, and 10 is the worst imaginable fatigue. The scoring should be done roughly at the same time during the day.

    Time frame: 6 months

  7. Change in Modified Ashworth Scale from baseline

    During the enrolment visit, Modified Ashworth Scale is assessed. The same will be recorded at month 6.

    Time frame: 6 months

07

Study locations

1 site
  • Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway
    Bergen, Bergen 5839, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jan 2024, 13 months.

Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 13 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Jun 2023 → Jan 2024 and completion Dec 2023 → Jan 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2022
First posted
Oct 28, 2022
StartActual
Nov 4, 2022
Primary completionActual
Jan 2, 2024was Jun 2023
CompletionActual
Jan 2, 2024was Dec 2023
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 19, 2026
Sites
1 site added, 1 site removed
Show site
  • Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway · Bergen, Norway
Show 1 removed
  • Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway · Bergen, Norway
Oct 19, 2026
Primary completion
Jun 30, 2023→Jan 2, 2024 (actual)
Oct 19, 2026
Study completion
Dec 31, 2023→Jan 2, 2024 (actual)
Oct 19, 2026
Enrollment
60 (estimated)→58 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway · Bergen, Norway
    Show 1 removed
    • Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway · Bergen, Norway
    Primary completion Jun 30, 2023→Jan 2, 2024 (now actual)
    Study completion Dec 31, 2023→Jan 2, 2024 (now actual)
    Enrollment 60 (estimated)→58 (actual)
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05598736
Lead sponsor
Otivio AS
Responsible party
Sponsor
First posted
Oct 28, 2022
Start date
Nov 4, 2022
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Last update
Oct 19, 2026

Study contacts

Kjell-Morten Myhr, MD, PhD
principal investigator · Dept. of Neurology Haukeland Univ. Hosp. & Dept. of Clin. Med, Univ. of Bergen, Norway
Peter Vestergaard Rasmussen, MD, PhD
principal investigator · Department of Clinical Medicine - The Department of Neurology, Aarhus University
Sara Haghighi Mobarhan Smith, MD, PhD
principal investigator · Linköping University, Linköping, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion